ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1069

Significantly Elevated Serum Protein-Adduction with 4-Hydroxy-2-Nonenal but Not Malondialdehyde in Sjogren’s Syndrome

Biji T Kurien1,2,3, Sona Nuguri4, Bre'ana Byrd5, Joey Maher6, Rohit Thomas4, Huyen Tran7 and R. Hal Scofield8, 1Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 2U.S. Department of Veterans Affairs Medical Center, Oklahoma City, OK, 3College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 4Oklahoma School of Science and Mathematics, Oklahoma City, OK, 5University of Central Oklahoma, Edmond, OK, 6University of Oklahoma, Norman, OK, 7University of Oklahoma Health Sciences Center, Edmond, OK, 8Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation; Department of Medicine, University of Oklahoma Health Sciences Center; US Department of Veterans Affairs Medical Center, Oklahoma City, OK

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Autoantibodies and autoimmune diseases, Sjogren's syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Innate Immunity and Rheumatic Disease Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Sjögren’s syndrome (SS) is a chronic inflammatory, autoimmune disorder characterized by diminished lacrimal and salivary gland secretion resulting in keratoconjunctivitis sicca and xerostomia. Autoantibodies, directed against 60 kD Ro protein is found in up to 90% of patients with SS. Free radical mediated oxidative damage has not been well characterized previously in SS. Therefore, we studied oxidative damage (conjugate diene formation) and modification of serum proteins by the lipid peroxidation by-product 4-hydroxy-2-nonenal (HNE) or malondialdehyde (MDA) in SS and age-and sex matched controls.

Methods:

Sixty nine primary SS subjects, 25 age and sex matched subjects that do not meet criteria (incomplete SS), and 18 normal controls were studied. We studied indices of oxidative damage, namely conjugate diene formation, and HNE or MDA-protein adducts in the sera of SS, incomplete SS and normal controls. Sera from SS subjects or normal controls were coated on ELISA plates as antigen. HNE or MDA adducts in serum proteins was determined with rabbit anti-HNE or anti-MDA antibodies purchased commercially. Sera from SS or normal controls were electrophoresed, transferred to nitrocellulose by electroblotting and subjected to immunoblotting with rabbit anti-HNE antibody. For determination of conjugate diene, 25 µl of SS or incomplete SS sera were extracted with chloroform:methanol (2:1) and the samples were centrifuged. Two ml of the clear supernatant was evaporated to dryness at 45˚C and reconstituted in one ml methanol. The spectra ranging from 200 to 360 nm was read using a spectrophotometer.

Results:

We found significantly increased oxidative damage in the sera of primary SS subjects compared to normal controls by ELISA and immunoblotting. Serum proteins from SS subjects were found to contain HNE adducts. There was significantly more HNE-modified proteins in SS sera (n=10) compared to controls (n=10; age and sex matched) by ELISA (0.074 ± 0.017 versus 0.046 ± 0.007; p=0.00015; average OD±SD). However, there was no significant difference in MDA-modified proteins between SS and controls by ELISA. When SS sera (n=34) were analyzed by immunoblotting, we found HNE adducts in several serum proteins, and significantly in a 18 kD protein. Control sera did not show significant HNE-modification (n=8). Our preliminary results for conjugate diene formation show that there is no significant difference between conjugate diene levels in the Sjogrens’s syndrome patients (n=25) and incomplete SS subjects (n=25). We are pursuing HNE-modification in the sera of incomplete SS subjects and also identifying the protein bands in SS subjects with HNE adducts by matrix assisted time of flight mass spectrometry.

Conclusion:

Significantly elevated HNE- but not MDA-protein adducts occur in the sera of SS subjects compared to normal controls, showing that oxidative damage occurs in SS.


Disclosure: B. T. Kurien, None; S. Nuguri, None; B. Byrd, None; J. Maher, None; R. Thomas, None; H. Tran, None; R. H. Scofield, None.

To cite this abstract in AMA style:

Kurien BT, Nuguri S, Byrd B, Maher J, Thomas R, Tran H, Scofield RH. Significantly Elevated Serum Protein-Adduction with 4-Hydroxy-2-Nonenal but Not Malondialdehyde in Sjogren’s Syndrome [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/significantly-elevated-serum-protein-adduction-with-4-hydroxy-2-nonenal-but-not-malondialdehyde-in-sjogrens-syndrome/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/significantly-elevated-serum-protein-adduction-with-4-hydroxy-2-nonenal-but-not-malondialdehyde-in-sjogrens-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology